Podcasts about helixnano

Victoria Song began her professional journey as a venture capitalist but noticed how each achievement only made her feel empty. That was until a lightbulb moment during business school inspired her to figure out how entrepreneurs could maximize their own satisfaction while striving for success. Victoria traveled far lengths to study, train, and work with over 24 of the best coaches, therapists, and healers in the world. In her studies, she discovered how tapping into the subconscious mind to reveal an individual's true purpose could mean the difference between being an "okay" business to a global leading company. Victoria is now a Leadership Advisor to the fastest growing tech companies in Silicon Valley - mentoring the likes of Ryan Hudson, Co-Founder of Honey, acquired by PayPal for $4 Billion, & Hannu Rajaniemi, Co-Founder & CEO of HelixNano. We also discuss her exciting WSJ - Bestseller, Bending Reality: How to Make the Impossible Probable.✅How to find Victoria Book: https://victoriasong.me/bending-reality/✅Follow our socials @goentrepreneuryourself✅Subscribe to our soon-to-arrive newsletter for digestible entrepreneur tips, resources from our guests, and the latest business memes at Goentrepreneuryourself.com✅Leave us a review on Apple Podcast!

Could all the leading COVID19 vaccines have a fatal flaw in their design? A dizzying number of vaccines are being developed to protect society from the dangers of COVID19, each with its own benefits and pitfalls. At HelixNano, Nikolai Eroshenko and his team are designing a special type of vaccine with increased attention to ensuring that this protective medicine doesn't accidentally improve the virus's ability to infect cells or drive the immune system to cause collateral damage. Nikolai describes how vaccines work, why so many are being developed to fight SARS-CoV-2, and how technological advances have allowed us to develop them faster than ever before. Most importantly, Nikolai calls on all vaccine developers to put more effort into their design and testing pipeline such that they don’t accidentally help the virus become more deadly. About the AuthorNikolai earned his PhD under Professor George Church, one of the founding fathers of synthetic biology. The lab is renowned for developing high throughput methods to design, build, and test bioengineered parts.The technology Nikolai designed in the Church lab was spun out into a company, HelixNano, to design next-generation vaccines to treat and prevent cancer.When the COVID19 pandemic hit, Nikolai and HelixNano made an all-hands-on-deck pivot to create a COVID19 vaccine without the possibility of triggering antibody-dependent enhancement, an effect that can cause a vaccine to increase the deadliness of SAR-CoV-2.Key TakeawaysVaccines train an immune response by creating specialized T cells and antibodies that protect people from future infections of the virus.A mechanism called antibody-dependent enhancement, or ADE, could allow current vaccines to accidentally help SARS-CoV-2 infect people who have received it.Nikolai calls on vaccine developers to improve their measurement capabilities so that they can catch the potential for ADE early.The current boon of new biotechnology has allowed us to test and measure the effectiveness and safety of these lifesaving technologies faster than ever before.TranslationNikolai and his team focus on one specific type of vaccine that uses RNA to elicit an immune response.Using RNA allows for fast design-build-test cycles that HelixNano uses to rapidly screen for novel vaccine properties.HelixNano is developing a vaccine that is specifically designed to minimize the chance of ADE.First Author: Nikolai EroshenkoPaper: Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nature, 2020.Follow Fifty Years on Twitter!If you’re an author of an upcoming paper in bio or know of any interesting papers dropping soon and want to hear from the authors, drop us an email at translation [AT] fifty [DOT] vc.

This is a a live panel ran by SOSV to introduce and discuss solutions funded by some of the most active investors in deep tech startups fighting Covid-19. Each of the three funds (Fifty Years, Khosla Ventures, SOSV) published an impressive list of their relevant portfolio startups. IndieBio even made a call to fund Covid-fighting startups as part of its newly launched NYC program. Here are the full video and slides. If you’d like to know about future events, follow us on Twitter at @SOSV or sign up to our newsletter.   This podcast is hosted by Benjamin Joffe, Partner at SOSV, a global early stage fund focused on deep tech with over $700m under management. SOSV runs multiple accelerator programs, including HAX (intelligent hardware) and IndieBio (life sciences). Episode Overview This recording has 3 parts: Part 1: Some non-biotech solutions, from 3D printing to robotics, Part 2, VCs present solutions from their portfolio (mostly biotech), Part 3: Q&A.   The speakers are: Seth Bannon, Founding Partner at Fifty Years, Alex Morgan, MD PhD, Partner at Khosla Ventures, Jun Axup, PhD, Partner at IndieBio (SOSV).   Introduction & Moderation: Benjamin Joffe, Partner at SOSV Julie Wolf, PhD, Communications Director at IndieBio NYC (SOSV)   Part 1 Introduction by Benjamin Joffe, Partner at SOSV a. What has changed since SARS? SARS was in 2003. In the span of 17 years, several important developments happened: Low-cost genetic tests Sensors & robots Cloud solutions   The challenge of current solutions remain costs, timing and scalability. b. Prevention A hundred years ago, prevention was mostly... masks. Today, we have a much better understanding of the modes of infection of viruses, and many new tools to prevent it. c. 3D Printing While we’re still far from the ‘3D printing revolution’ that was announced 10 years ago, some high-resolution 3D printing technology is able to supply useful parts quickly, at low cost, and on-site. Clips and buckles for masks or door handles but also test swabs. d. Protecting our face We need to protect our face from others, but also from ourselves: Many masks don’t effectively protect against infection as the virus is too small (about 120nm). Verdex (a SOSV portfolio company) has developed a nanofiber material that filters out particles above 100nm — effectively blocking the virus — and is also more breathable. HabitAware, a HAX portfolio company, had created a machine-learning-powered bracelet to prevent body-focused repetitive behaviors (e.g. nail biting) by recognizing and alerting of specific gestures. The pandemic provided a new direct application of their technology.   e. Disinfecting everything The ‘new normal’ is making frequent and thorough disinfection of our living and working environment necessary, to protect us and helps us get back to work. HAX has invested in various solutions for this, from floor cleaning (Avidbots) to toilet cleaning (Somatic). The dry cleaning robot startup Presso announced its solution initially intended for business travels was now in high-demand with movie and TV studios who are resuming operations. Youibot, an autonomous logistics startup, managed to repurpose their technology to provide disinfection with UV-C lights, and temperature detection.   f. Testing with devices On the testing front, several countries have introduced testing stations that look like phone booths. Some are also using helmets with IR sensors to detect potential infections. Some wearable device companies like Oura and Strados Labs are applying their technology to pre-symptom detection or monitoring. g. Treatment Treating the virus is complicated, as it might also involve treating the immune response, and support the recovery of patients. Various large and small companies are working on vaccine candidates, Some companies are trying to develop new drugs, or repurpose existing ones for a faster time-to-market   The lack of equipment — particularly respirators — is being addressed partly by repurposing other devices. Among them are snorkeling masks and BIPAP/CPAP machines. Finally, alongside this pandemic comes tremendous emotional harm due to stress, economic uncertainty and unemployment. Some companies such as Feel are working on low-cost solutions to help people improve their mental health. Part 2 Seth Bannon, Founding Partner at Fifty Years The Covid-19 threat is reminiscent of WWII, with potential deaths in the tens of millions. WWII gave us many tech innovations such as: mass production of antibiotics, blood plasma as a therapeutic solution, skin grafts, flu vaccine, radar, microwave ovens, pressurized plane cabins, nuclear power and the first programmable digital computer. It laid the foundation of technical progress for many years to come. A similar rally today could build solutions for the future. Everyone who can help should help, and 17 of our portfolio companies did. HelixNano (from the George Church lab at Harvard). Working on a vaccine to counteract SARS-Cov-2 evolutions and antigenic drift. BillionToOne found a way to run a test on Sanger sequencers at low cost and high volume. Opentrons (a co-investment with Khosla and SOSV) built a low-cost lab robot to automate liquid handling, already deployed in multiple labs around the world to test covid. Voodoo Manufacturing directed their cloud farm of 3D printers to focus on combating Covid-19 by producing PPE and more at cost. Solugen, that makes hydrogen peroxide, realized they had the capacity to make hand sanitizer and now do so pro-bono.   Alex Morgan, Partner at Khosla Ventures Khosla has over $1B under management, including a main and seed fund. The goal is to ‘reinvent social infrastructure with technology’, looking for investments combining financial returns with societal impact (e.g. Impossible Foods, Color, etc.). We also have a list of companies responding to Covid-19. Genalyte has a FDA-approved testing solution that takes 15min. Current capacity is about~250k patients / month. Luminostics designed an optical test that cane be run with a small device attached to a phone. Pardes Bio is a recent investment working on a therapeutic using a protease inhibitor. Prellis Biologics (IndieBio/SOSV co-investment) is a tissue engineering company that can 3d print lymph nodes ex vivo to produce therapeutic antibodies (here are a recent video interview and media coverage). Some other investments also focus on the distribution of care, and particularly mental health, such as Ginger (remote service for mental health) and Flow Neuroscience (a SOSV/HAX co-investment offering a drug-free treatment for depression using an at-home brain stimulation device, already on sale in EU/UK).   Jun Axup, Chief Science Officer & Partner at IndieBio IndieBio is the life sciences accelerator program of SOSV, based in SF and NYC and investing globally. It invested in 136 companies including Memphis Meats, Clara Food and Perfect Day in the cellAg space. CASPR Biotech uses CRISPR for low-cost testing (covered by NYT). Renegade.Bio was founded as a lab to test at high speed and large volume. ANA Therapeutics is repurposing an anti-worm treatment toward Zika, SARS and now Covid. Halomine found a way to keep surfaces free of viruses by stabilizing chlorine, making the protective film last up to 30 days instead mere hours. SmartSteward can track outbreaks within nursing homes, using algorithms to scan metadata from electronic health records and lab reports in real time, identifying critical changing patterns.   The biotech renaissance is strong, but still has many unknowns: Are pandemics a new investable thesis? How do we get back to work, protect everyone? We need to stay nimble, and keep evolving.   Part 3 Q&A moderated by Julie Wolf, Communications Director at IndieBio Q: How did IndieBio decide to invest in Covid solutions? Jun Axup (IndieBio/SOSV): Several are alumni who pivoted (e.g. Prellis), some simply needed more funding (e.g. Caspr.bio), some were opportunistic investments and some more philanthropic. The key was to fund companies who could have impact now rather than in a year. Q: For Khosla's startups, are pivots to Covid risky? Alex Morgan (Khosla Ventures): It varies a lot. Ideally we want to see long-term opportunities. Prellis, for example, are seizing an opportunity within a long-term plan. One challenge for diagnostic technologies is how you get paid, which is exposed to regulatory or policy risks. The landscape is changing and susceptible even to the election cycle. The current situation that delayed many procedures and treatments might push for a ‘pay for outcome’ model, which is more aligned with our investment model and the interests of patients. Q: How is 50Y looking at investing into Covid-related tech? Seth Bannon (Fifty Years): First, we offered a $25,000 uncapped note no questions asked to support any of our portfolio company who felt they had some kind of solution. For those needed more capital we had longer conversations. For new investments we don’t want to fund ‘covid-only’ solutions because it might be too difficult to build a business around, but most likely have applications beyond this pandemic, or beyond pandemics in general. For instance companies building infrastructure solutions, or take vaccine development from years to months, or found better ways to repurpose drugs. We’d love to see a great solution for at-home testing, maybe something CRISPR-based. Q: What is your biggest challenge in finding companies to invest in? Jun Axup (IndieBio/SOSV): Deployment and scaling is the hardest. We fund super early companies and getting through both regulations and manufacturing is a challenge, so we prefer teams that have some understanding of how to do that. Alex Morgan (Khosla Ventures): There is a lack of backchannel conversations that are not happening because [because of SIP/WFH], which could help find out about new companies or research. We’re trying with other media. Seth Bannon (Fifty Years): Because of the many solutions being developed, it is a challenge to find solutions that are uniquely suited to the pandemic, and whose solution and business would outlast it. Thanks to our speakers for their insights and to our audience for great questions! Speakers can be contacted at Twitter: Jun Axup (@junaxup, @indbio, @SOSV), Alex Morgan (@genomicsdoc or @khoslaventures) Seth Bannon (@sethbannon or @fiftyyears). Some of the remaining questions are on Twitter for further discussion. Resources Video and slides of the event. 50Y companies tackling the novel coronavirus SARS-CoV-2  Khosla Ventures’ entrepreneurs are responding with amazing diversity to COVID-19 solutions for society’s needs Top SOSV Startups Combatting COVID-19 IndieBio Coronavirus Initiative Previous Episodes Eric Rosenblum (Tsingyuan Ventures) on the Chinese Tech Diaspora Opportunity  Overview of Deep Tech Investment, Based on the Report by Different Sota Nagano (Abies Ventures) on Japan’s Deep Tech Scene Seth Bannon (Fifty Years) on Solving Global Problems Kelly Chen (DCVC) on Investing in Old School Industries Manish Singhal (pi Ventures) on India’s Deep Tech Scene John Ho (Anzu Partners) on Breakthrough Industrial Tech Matt Clifford (EF / Entrepreneur First) on Investing in Talent and Pre-Product Subscribe Podcast: Apple Podcast, Google Podcast, Spotify, etc. Twitter: @LabToMarket

Welcome to the fourteenth episode of the Palladium Podcast, where we explore the future of governance and society. This week, Jonah Bennett and Wolf Tivy talk about science fiction with Hannu Rajaniemi, a New York Times published science fiction writer and biotech startup founder. He’s currently CEO of HelixNano, which works on developing novel therapeutic modalities for cancer.

Scifi author, scientist, and entrepreneur Hannu Rajaniemi discusses the real life late Victorian attempts to map the afterlife which inspired Summerland, his latest novel. Rajaniemi introduces us to scientists, inventors, misfits, revolutionaries, plus a tour of obscure ideas and bizarre inventions: spirit-powered sewing machines, aetheric knots, the four-dimensional geometry of Lenin’s tomb... What do these actual Victorian obsessions tell us about today’s fascination with intelligent machines and immortality? He'll sign after the talk, and Borderlands Books will be on hand selling all of his books and he will sign after the talk. Hannu Rajaniemi was born in Finland, obtained his PhD in string theory at the University of Edinburgh and now works as a co-founder and CTO of HelixNano, a synthetic biology startup based in the Bay Area. He is the author of four novels including The Quantum Thief trilogy and Summerland.

Main Fiction: "Elegy for a Young Elk" by Hannu RajaniemiOriginally published in Subterranean, reprinted in Invisible PlanetsHannu Rajaniemi was born in Finland. At the age of eight he approached the European Space Agency with a fusion-powered spaceship design, which was received with a polite “thank you” note. Hannu studied mathematics and theoretical physics at University of Oulu and Cambridge and holds a PhD in string theory from the University of Edinburgh. He co-founded a mathematics consultancy whose clients included UK Ministry of Defence. Currently, he works as a co-founder of HelixNano, a synthetic biology startup. Hannu is the author of four novels including The Quantum Thief (translated into more than 20 languages), the forthcoming Summerland (July 2018), and several short stories. He lives in the San Francisco Bay Area.Narrated by Al BarclayAl Barclay has worked extensively over 15 years, most notably playing opposite James McAvoy and Michael Sheen in Stephen Fry’s Bright Young Things, and with David Thewlis in Luc Besson’s The Lady. He will be in the West End at The Arts Theatre this December playing Scrooge in A Christmas Carol.He also once drank two bottles of gin with Peter O’Toole, and danced the night away in Camden with Amy Winehouse.Fact: Looking Back at Genre History 100!!! by Amy H Sturgis See acast.com/privacy for privacy and opt-out information.